177 related articles for article (PubMed ID: 15102604)
1. Development of secreted proteins as biotherapeutic agents.
Bonin-Debs AL; Boche I; Gille H; Brinkmann U
Expert Opin Biol Ther; 2004 Apr; 4(4):551-8. PubMed ID: 15102604
[TBL] [Abstract][Full Text] [Related]
2. Longer action means better drug: tuning up protein therapeutics.
Szlachcic A; Zakrzewska M; Otlewski J
Biotechnol Adv; 2011; 29(4):436-41. PubMed ID: 21443940
[TBL] [Abstract][Full Text] [Related]
3. Chemoenzymatic synthesis of small molecule human therapeutics.
Ran N; Rui E; Liu J; Tao J
Curr Pharm Des; 2009; 15(2):134-52. PubMed ID: 19149609
[TBL] [Abstract][Full Text] [Related]
4. Recent progress in biomolecular engineering.
Ryu DD; Nam DH
Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. Drug discovery in the extracellular matrix.
Huxley-Jones J; Foord SM; Barnes MR
Drug Discov Today; 2008 Aug; 13(15-16):685-94. PubMed ID: 18583179
[TBL] [Abstract][Full Text] [Related]
7. Negative design for improved therapeutic proteins.
Desjarlais JR; Lazar GA
Trends Biotechnol; 2003 Oct; 21(10):425-7. PubMed ID: 14512227
[No Abstract] [Full Text] [Related]
8. Strategies for extended serum half-life of protein therapeutics.
Kontermann RE
Curr Opin Biotechnol; 2011 Dec; 22(6):868-76. PubMed ID: 21862310
[TBL] [Abstract][Full Text] [Related]
9. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic proteins: A to Z.
Ozgur A; Tutar Y
Protein Pept Lett; 2013 Dec; 20(12):1365-72. PubMed ID: 24261980
[TBL] [Abstract][Full Text] [Related]
11. Rational design and engineering of therapeutic proteins.
Marshall SA; Lazar GA; Chirino AJ; Desjarlais JR
Drug Discov Today; 2003 Mar; 8(5):212-21. PubMed ID: 12634013
[TBL] [Abstract][Full Text] [Related]
12. Introduction to current and future protein therapeutics: a protein engineering perspective.
Carter PJ
Exp Cell Res; 2011 May; 317(9):1261-9. PubMed ID: 21371474
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies as therapeutics in human malignancies.
Pandey M; Mahadevan D
Future Oncol; 2014 Mar; 10(4):609-36. PubMed ID: 24754592
[TBL] [Abstract][Full Text] [Related]
14. In-depth proteomic profiling of the uveal melanoma secretome.
Angi M; Kalirai H; Prendergast S; Simpson D; Hammond DE; Madigan MC; Beynon RJ; Coupland SE
Oncotarget; 2016 Aug; 7(31):49623-49635. PubMed ID: 27391064
[TBL] [Abstract][Full Text] [Related]
15. Drug products of recombinant DNA technology.
Black WJ
Am J Hosp Pharm; 1989 Sep; 46(9):1834-44. PubMed ID: 2679063
[TBL] [Abstract][Full Text] [Related]
16. Discovery and development of biopharmaceuticals: current issues.
Strohl WR; Knight DM
Curr Opin Biotechnol; 2009 Dec; 20(6):668-72. PubMed ID: 19896824
[No Abstract] [Full Text] [Related]
17. Exploiting directed evolution for the discovery of biologicals.
Douthwaite J; Jermutus L
Curr Opin Drug Discov Devel; 2006 Mar; 9(2):269-75. PubMed ID: 16566297
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of protein therapeutics.
De Groot AS; Scott DW
Trends Immunol; 2007 Nov; 28(11):482-90. PubMed ID: 17964218
[TBL] [Abstract][Full Text] [Related]
19. Peptide-based drug design: here and now.
Otvos L
Methods Mol Biol; 2008; 494():1-8. PubMed ID: 18726565
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
